Functions of CAFs in microenvironment of non-small cell lung cancer: based on updated hallmarks of cancer-Reference-Cited by-同舟云学术

Functions of CAFs in microenvironment of non-small cell lung cancer: based on updated hallmarks of cancer

Published:2024-09-02 Issue: Volume: Page:
ISSN:1765-2839
Container-title:Oncologie
language:en
Short-container-title:

Author:

Feng Xiaoyan¹,Zhu Binghan²,Peng Yali¹,Zhang Kaiyuan²,Wang Yangchun¹,Huang Guichun³,Li Yan¹²

Affiliation:

1. Department of Respiratory Medicine, Nanjing Drum Tower Hospital , The Affiliated Hospital of Nanjing University Medical School , Nanjing , Jiangsu , China

2. Department of Respiratory Medicine , Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine , Nanjing , Jiangsu , China

3. Medical School , 12581 Nanjing University , Nanjing , Jiangsu , P.R. China

Abstract

Abstract Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, which ranks as the first malignant tumor in mortality. The occurrence and development of NSCLC are closely related to the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are considered to be critical regulators of the occurrence and development of NSCLC, which have essential effects on multiple biological characteristics of NSCLC. The hallmarks of cancer biology have been updated recently, however, there are no reviews revisiting the function of CAFs in tumor microenvironment. This article reviews the origin, markers, and classification of CAFs, their impacts on the characteristics of NSCLC, and potential therapeutic targets of CAFs to help develop individualized treatment plans for NSCLC.

Funder

Natural Science Foundation of Jiangsu Province

Nanjing Municipal Health and Family Planning Commission

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/oncologie-2024-0232/pdf

Reference62 articles.

1. Siegel, RL, Giaquinto, AN, Jemal, A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49. https://doi.org/10.3322/caac.21820.

2. Zhang, Y, Vaccarella, S, Morgan, E, Li, M, Etxeberria, J, Chokunonga, E, et al.. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol 2023;24:1206–18. https://doi.org/10.1016/s1470-2045(23)00444-8.

3. Kratzer, TB, Bandi, P, Freedman, ND, Smith, RA, Travis, WD, Jemal, A, et al.. Lung cancer statistics, 2023. Cancer 2024;130:1330–48. https://doi.org/10.1002/cncr.35128.

4. Li, S, Meng, C, Hao, Q, Zhou, R, Dai, L, Guo, Y, et al.. “On/off” – switchable crosslinked PTX-nanoformulation with improved precise delivery for NSCLC brain metastases and restrained adverse reaction over nab-PTX. Biomaterials 2024;307:122537. https://doi.org/10.1016/j.biomaterials.2024.122537.

5. Nakamichi, S, Kubota, K, Misumi, T, Kondo, T, Murakami, S, Shiraishi, Y, et al.. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small cell lung cancer: TORG1937 (DATE study). Clin Cancer Res 2024;30:1104–10. https://doi.org/10.1158/1078-0432.ccr-23-2568.